1. Scrip
  2. >>New Products

Could Postponement of Intercept’s Expected NASH Panel Impact Its PDUFA Date?

 
• By Joseph Haas

CDER’s postponing of meetings planned through the end of April likely means a later advisory committee date to review OCA in NASH. The US PDUFA date previously was pushed back to late June.

Building icon with inscription FDA and flag of The United States over abstract background. - Illustration
The status of imminent advisory committee reviews is in question with CDER's meeting cancellation notice

Ramifications of the novel coronavirus COVID-19 continue to bring business interruptions for the biopharmaceutical industry, including the 10 March announcement by the US Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) that all external meetings through the end of April are being postponed. For Intercept Pharmaceuticals Inc., that likely means a later date than expected for the advisory committee review of obeticholic acid (OCA) for non-alcoholic steatohepatitis (NASH).

The FDA did not respond to an inquiry about the status of Intercept advisory committee, which is widely expected –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Psoriasis Submissions Iin The Bag, J&J Advances Icotrokinra Into Phase III For Ulcerative Colitis

 
• By Kevin Grogan

The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.

Boehringer’s Jascayd Approval Brings New Mechanism To IPF

 
• By Jessica Merrill

The PDE4B inhibitor brings a new mechanism of action to the challenging respiratory disease and is the first drug approved for the indication in more than a decade.

Galderma Punches Above Its Weight Against Dermatology Goliaths

 
• By Kevin Grogan

The Swiss group is more than holding its own against Dupixent for prurigo nodularis and is looking to make further inroads into Sanofi and Regeneron's blockbuster's market share in atopic dermatitis.

Pipeline Watch: Five Approvals And 15 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Sakaguchi’s Nobel Brings Cheer To Japan Biopharma

 
• By Lisa Takagi

Japan's latest Nobel Prize win sparks hopes for renewed investment in biopharma R&D by the national government, including in a venture co-founded by the winner.

Already Strained Health Care Capacity To Be Tested By Larger CAR-T Indications

 
• By Mandy Jackson

Speakers at ARM’s Cell and Gene Meeting on the Mesa highlighted challenges of CAR-T’s evolution from niche to mainstream therapy given health care providers’ limited capacity to deliver the complex care associated with the products.

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.